These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 15927989)
41. Targeting endothelial dysfunction in vascular complications associated with diabetes. Sharma A; Bernatchez PN; de Haan JB Int J Vasc Med; 2012; 2012():750126. PubMed ID: 22013533 [TBL] [Abstract][Full Text] [Related]
42. Rho kinase as a therapeutic target in cardiovascular disease. Surma M; Wei L; Shi J Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346 [TBL] [Abstract][Full Text] [Related]
43. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Zhou H; Li YJ; Wang M; Zhang LH; Guo BY; Zhao ZS; Meng FL; Deng YG; Wang RY Acta Pharmacol Sin; 2011 Aug; 32(8):999-1008. PubMed ID: 21743486 [TBL] [Abstract][Full Text] [Related]
45. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Zhou Q; Gensch C; Liao JK Trends Pharmacol Sci; 2011 Mar; 32(3):167-73. PubMed ID: 21242007 [TBL] [Abstract][Full Text] [Related]
46. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Hata T; Goto C; Soga J; Hidaka T; Fujii Y; Idei N; Fujimura N; Maruhashi T; Mikami S; Kihara Y; Chayama K; Noma K; Liao JK; Higashi Y Atherosclerosis; 2011 Jan; 214(1):117-21. PubMed ID: 21035804 [TBL] [Abstract][Full Text] [Related]
47. The role of Rho protein signaling in hypertension. Loirand G; Pacaud P Nat Rev Cardiol; 2010 Nov; 7(11):637-47. PubMed ID: 20808285 [TBL] [Abstract][Full Text] [Related]
48. Urotensin II alters vascular reactivity in animals subjected to volume overload. Harris GS; Lust RM; Katwa LC; Wingard CJ Peptides; 2010 Nov; 31(11):2075-82. PubMed ID: 20723572 [TBL] [Abstract][Full Text] [Related]
49. RhoA/Rho-kinase and vascular diseases: what is the link? Nunes KP; Rigsby CS; Webb RC Cell Mol Life Sci; 2010 Nov; 67(22):3823-36. PubMed ID: 20668910 [TBL] [Abstract][Full Text] [Related]
50. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Dong M; Yan BP; Liao JK; Lam YY; Yip GW; Yu CM Drug Discov Today; 2010 Aug; 15(15-16):622-9. PubMed ID: 20601092 [TBL] [Abstract][Full Text] [Related]
51. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Small EM; Thatcher JE; Sutherland LB; Kinoshita H; Gerard RD; Richardson JA; Dimaio JM; Sadek H; Kuwahara K; Olson EN Circ Res; 2010 Jul; 107(2):294-304. PubMed ID: 20558820 [TBL] [Abstract][Full Text] [Related]
52. New approaches to the treatment of pulmonary hypertension: from bench to bedside. Murthy SN; Nossaman BD; Kadowitz PJ Cardiol Rev; 2010; 18(2):76-84. PubMed ID: 20160533 [TBL] [Abstract][Full Text] [Related]
53. The pericyte: cellular regulator of microvascular blood flow. Kutcher ME; Herman IM Microvasc Res; 2009 May; 77(3):235-46. PubMed ID: 19323975 [TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Hata Y; Miura M; Nakao S; Kawahara S; Kita T; Ishibashi T Jpn J Ophthalmol; 2008; 52(1):16-23. PubMed ID: 18369695 [TBL] [Abstract][Full Text] [Related]